Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125758771 | 12575877 | 1 | I | 20160707 | 20160720 | 20160720 | PER | US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-057511 | BRISTOL MYERS SQUIBB | 0.00 | F | Y | 68.00000 | KG | 20160720 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125758771 | 12575877 | 1 | PS | SPRYCEL | DASATINIB | 1 | Oral | 100 MG, QD | U | U | 21986 | 100 | MG | QD | |||||
| 125758771 | 12575877 | 2 | C | ENALAPRIL | ENALAPRIL | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125758771 | 12575877 | 1 | Chronic myeloid leukaemia |
| 125758771 | 12575877 | 2 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125758771 | 12575877 | Diarrhoea | |
| 125758771 | 12575877 | Fluid retention |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125758771 | 12575877 | 1 | 2016 | 0 |